FOLD Amicus Therapeutics Inc

Price (delayed)

$10.62

Market cap

$2.83B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.97

Enterprise value

$3.08B

Highlights
Amicus Therapeutics's gross profit has increased by 28% YoY and by 2.6% QoQ
FOLD's revenue is up by 28% year-on-year and by 2.3% since the previous quarter
FOLD's debt has surged by 110% year-on-year
The equity has contracted by 38% YoY and by 12% from the previous quarter

Key stats

What are the main financial stats of FOLD
Market
Shares outstanding
266.06M
Market cap
$2.83B
Enterprise value
$3.08B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
11.19
Price to sales (P/S)
10.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.55
Earnings
Revenue
$266.76M
EBIT
-$223.06M
EBITDA
-$214.38M
Free cash flow
-$200.99M
Per share
EPS
-$0.97
Free cash flow per share
-$0.76
Book value per share
$0.95
Revenue per share
$1.01
TBVPS
$2.32
Balance sheet
Total assets
$810.03M
Total liabilities
$559.14M
Debt
$440.98M
Equity
$250.9M
Working capital
$403.24M
Liquidity
Debt to equity
1.76
Current ratio
5.05
Quick ratio
4.64
Net debt/EBITDA
-1.19
Margins
EBITDA margin
-80.4%
Gross margin
88.4%
Net margin
-95.1%
Operating margin
-82.2%
Efficiency
Return on assets
-30.7%
Return on equity
-83.2%
Return on invested capital
-31.2%
Return on capital employed
-31.4%
Return on sales
-83.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FOLD stock price

How has the Amicus Therapeutics stock price performed over time
Intraday
-0.84%
1 week
12.03%
1 month
10.63%
1 year
-4.07%
YTD
-54.01%
QTD
7.49%

Financial performance

How have Amicus Therapeutics's revenue and profit performed over time
Revenue
$266.76M
Gross profit
$235.73M
Operating income
-$219.31M
Net income
-$253.57M
Gross margin
88.4%
Net margin
-95.1%
The operating margin rose by 42% YoY and by 12% QoQ
FOLD's net margin is up by 39% year-on-year and by 10% since the previous quarter
Amicus Therapeutics's gross profit has increased by 28% YoY and by 2.6% QoQ
FOLD's revenue is up by 28% year-on-year and by 2.3% since the previous quarter

Growth

What is Amicus Therapeutics's growth rate over time

Valuation

What is Amicus Therapeutics stock price valuation
P/E
N/A
P/B
11.19
P/S
10.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.55
The EPS has grown by 25% YoY and by 9% from the previous quarter
The P/B is 70% above the 5-year quarterly average of 6.6 but 16% below the last 4 quarters average of 13.4
The equity has contracted by 38% YoY and by 12% from the previous quarter
FOLD's price to sales (P/S) is 84% lower than its 5-year quarterly average of 67.5 and 35% lower than its last 4 quarters average of 16.2
FOLD's revenue is up by 28% year-on-year and by 2.3% since the previous quarter

Efficiency

How efficient is Amicus Therapeutics business performance
The ROS has grown by 43% YoY and by 13% from the previous quarter
The ROIC has grown by 40% YoY and by 19% from the previous quarter
Amicus Therapeutics's return on equity has decreased by 30% YoY and by 3% QoQ
FOLD's ROA is up by 20% YoY and by 10% from the previous quarter

Dividends

What is FOLD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FOLD.

Financial health

How did Amicus Therapeutics financials performed over time
FOLD's total assets is 45% greater than its total liabilities
The total liabilities has soared by 67% YoY but it fell by 7% QoQ
Amicus Therapeutics's quick ratio has increased by 13% from the previous quarter and by 12% YoY
FOLD's debt is 76% greater than its equity
FOLD's debt has surged by 110% year-on-year
The equity has contracted by 38% YoY and by 12% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.